Symptom duration (y) | |||
Discriminative measure | All patients (n = 129) | ≤2 (n = 77) | >2 (n = 52) |
IPD | |||
Sensitivity | 83% (67/81) | 90% (36/40) | 76% (31/41) |
Specificity | 94% (45/48) | 95% (35/37) | 91% (10/11) |
PPV | 96% (67/70) | 95% (36/38) | 97% (31/32) |
NPV | 76% (45/59) | 90% (35/39) | 50% (10/20) |
APS | |||
Sensitivity | 63% (30/48) | 62% (23/37) | 64% (7/11) |
Specificity | 95% (77/81) | 98% (39/40) | 93% (38/41) |
PPV | 88% (30/34) | 96% (23/24) | 70% (7/10) |
NPV | 81% (77/95) | 74% (39/53) | 91% (38/42) |
MSA | |||
Sensitivity | 79% (11/14) | 73% (8/11) | — |
Specificity | 90% (18/20) | 92% (12/13) | — |
PPV | 85% (11/13) | 89% (8/9) | — |
NPV | 86% (18/21) | 80% (12/15) | — |
PSP | |||
Sensitivity | 100% (16/16) | 100% (12/12) | — |
Specificity | 94% (17/18) | 100% (12/12) | — |
PPV | 94% (16/17) | 100% (12/12) | — |
NPV | 100% (17/17) | 100% (12/12) | — |
Data are % (no. of subjects).